An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder

International Journal of Psychiatry in Clinical Practice

Volumn 18, Issue 1, 2014, Pages 11-15

  Kaplan, Alicia ^a   Franzen, Michael D ^a   Nickell, P V ^a   Ransom, Danielle ^b   Lebovitz, Paul J ^c  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c ALLEGHENY HEALTH NETWORK   (United States)

Author keywords

Duloxetine; Generalized anxiety disorder; Irritable bowel syndrome

Indexed keywords

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANXIETY DISORDERS; COMORBIDITY; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; PLACEBOS; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; THIOPHENES; YOUNG ADULT;

EID: 84894094555     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2013.838632     Document Type: Article

References (31)

1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders, 4Thedition, text revision. Washington, DC: American Psychiatric Association
2. Brennan BP, Fogarty KV, Roberts JL, Reynolds KA, Pope HG Jr, Hudson Jl. 2009. Duloxetine in the treatment of irritable bowel syndrome: An open-label pilot study. Hum Psychopharmacol 24: 423-428
3. Blanchard EB, Lackner JM, Jaccard J Rowell D, Carosella AM, Powell C, et al. 2008. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res 64: 119-128
4. Culpepper L. 2009. Generalized anxiety disorder and medical illness. J Clin Psychiatry 70: 20-24
5. Drossman DA. 2009. Beyond Tricyclics: New ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol 104: 2897-2902
6. Drossman DA. 1999. Do psychosocial factors defi ne symptom severity and patient status in irritable bowel syndrome? Am J Med 107: 41S-50S.
7. Drossman DA, Corazziari E. 2006. Rome III: The functional gastrointestinal disorders, 3rd edition. McLean, Virginia: Degnon Associates, Inc
8. Francis CY, Morris J, Whorwell PJ. 1997. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11: 395-402
9. Fritz CO, Morris PE, Richler JJ. 2012. Effect size estimates: Current use, calculations, and interpretation. J Exp Psychol Gen 141: 2-18
10. Grover M, Drossman DA. 2009. Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am 19: 151-170
11. Guy W. 1976. ECDEU-Assessment manual for psychopharmacology. Clinical Global Impression Scale. Bethesda, MD: National Institute of Mental Health
12. Halpert A, Drossman DA. 2005. Biopsychosocial issues in irritable bowel syndrome. J Clin Gastroenterol 39: 665-669
13. Halpert A, Dalton CB, Diamont NE, Toner BB, Hu Y, Morris CB, et al. 2005. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 100: 664-671
14. Lydiard RB. 1992. Anxiety and the irritable bowel syndrome. Psychiatric Ann 22: 612-618
15. Lydiard RB. 2005. Gut feelings: Irritable bowel syndrome and psychiatric disorders. CNS Spectr 10: 876
16. Lydiard RB, Falsetti A. 1999. Experience with anxiety and depression treatment studies: Implications for designing irritable bowel syndrome clinical trials. Am J Med 107: 65S-73S.
17. Lynn RB, Friedman LS. 1993. Irritable bowel syndrome. N Engl J Med 329: 1940-1945
18. Maier W, Buller R, Philipp M, Heuser I. 1988. The Hamilton Anxiety Scale: Reliability, validity and sensitivity to change in anxiety and depressive disorders. J Aff ect Disord 14: 61-68
19. Mayer EA, Naliboff BD, Chang L, Coutinho SV. 2001. V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 280: G519-G524
20. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, et al. 2005. The placebo Effect in irritable bowel syndrome trials: A meta-analysis. Neurogastroenterol Motil 17: 332-340
21. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. 1998. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig Dis Sci 43: 400-411
22. Ruscio AM, Lane M, Roy-Byrne PR, Stang PE, Stein DJ, Wittchen HU, Kessler RC. 2005. Should excessive worry be required for a diagnosis of generalized anxiety disorder? Results from the US National Comorbidity Survey Replication. Psychol Med 35: 1761-1772
23. Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J. 2008. Effi cacy and safety of duloxetine in the treatment of generalized anxiety disorder: A fl exible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25: 182-189
24. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Amorim P, Janavs J, Weiller E, et al. 1998. The Mini International Neuropsychiatric Interview (M.I.N.I): The development and validation of a structured diagnostic psychiatric interview. J Clin Psych 59: 22-33
25. Stein MB. 2009. Neurobiology of generalized anxiety disorder. J Clin Psychiatry 70: 15-19
26. Sussman N. 2003. SNRIs versus SSRIs: Mechanisms of action in treating depression and painful physical symptoms. Primary Care Companion J Clin Psychiatry 5: 19-26
27. Th ompson B. 2006. Foundations of behavioral statistics: An insightbased approach. New York: Guilford
28. Tollefson GD, Luxenberg M, Valentine R, Dunsmore G, Tollefson SL. 1991a. An open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder. J Clin Psych 52: 502-507
29. Tollefson GD, Tollefson SL, Pederson M, Luxenberg M, Dunsmore G. 1991b. Comorbid irritable bowel syndrome in patients with generalized anxiety and major depression. Ann Clin Psych 3: 215-222
30. Weisberg RB. 2009. Overview of generalized anxiety disorder: Epidemiology, presentation, and course. J Clin Psychiatry 70: 4-9
31. Whitehead WE, Palsson O, Jones KR. 2002. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 122: 1140-1156